BSE Live
Dec 15, 16:01Prev. Close
1279.65
Open Price
1278.45
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 15, 15:59Prev. Close
1279.30
Open Price
1274.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1280.60 (648)
| Key Financial Ratios of Dr Reddys Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 177.23 | 76.98 | 34.19 | 83.05 | 79.42 | |
| Diluted EPS (Rs.) | 176.88 | 76.85 | 34.12 | 82.88 | 79.14 | |
| Cash EPS (Rs.) | 224.24 | 123.97 | 80.78 | 127.82 | 117.44 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 914.07 | 764.10 | 711.31 | 699.67 | 680.27 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 914.07 | 764.10 | 711.31 | 699.67 | 680.27 | |
| Dividend / Share(Rs.) | 25.00 | 20.00 | 20.00 | 20.00 | 20.00 | |
| Revenue from Operations/Share (Rs.) | 713.02 | 640.09 | 563.81 | 586.24 | 598.34 | |
| PBDIT/Share (Rs.) | 217.38 | 152.90 | 92.40 | 140.94 | 155.26 | |
| PBIT/Share (Rs.) | 169.89 | 105.87 | 45.77 | 96.60 | 117.22 | |
| PBT/Share (Rs.) | 167.02 | 102.45 | 41.99 | 93.15 | 92.61 | |
| Net Profit/Share (Rs.) | 176.76 | 76.95 | 34.15 | 83.48 | 79.40 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 30.48 | 23.88 | 16.38 | 24.04 | 25.94 | |
| PBIT Margin (%) | 23.82 | 16.54 | 8.11 | 16.47 | 19.59 | |
| PBT Margin (%) | 23.42 | 16.00 | 7.44 | 15.89 | 15.47 | |
| Net Profit Margin (%) | 24.78 | 12.02 | 6.05 | 14.24 | 13.26 | |
| Return on Networth / Equity (%) | 19.33 | 10.07 | 4.80 | 11.93 | 11.67 | |
| Return on Capital Employed (%) | 18.46 | 13.34 | 6.13 | 13.14 | 10.61 | |
| Return on Assets (%) | 15.08 | 7.86 | 3.31 | 8.41 | 7.71 | |
| Total Debt/Equity (X) | 0.07 | 0.07 | 0.22 | 0.20 | 0.27 | |
| Asset Turnover Ratio (%) | 60.84 | 65.39 | 54.73 | 59.09 | 58.13 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.42 | 2.90 | 1.91 | 2.02 | 2.10 | |
| Quick Ratio (X) | 1.89 | 2.25 | 1.52 | 1.59 | 1.75 | |
| Inventory Turnover Ratio (X) | 5.41 | 5.27 | 5.04 | 5.37 | 6.01 | |
| Dividend Payout Ratio (NP) (%) | 13.32 | 25.99 | 70.41 | 24.22 | 25.13 | |
| Dividend Payout Ratio (CP) (%) | 10.50 | 16.13 | 29.76 | 15.82 | 16.99 | |
| Earnings Retention Ratio (%) | 86.68 | 74.01 | 29.59 | 75.78 | 74.87 | |
| Cash Earnings Retention Ratio (%) | 89.50 | 83.87 | 70.24 | 84.18 | 83.01 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 52,829.90 | 46,829.39 | 37,036.77 | 45,935.25 | 53,591.39 | |
| EV/Net Operating Revenue (X) | 4.46 | 4.41 | 3.96 | 4.73 | 5.25 | |
| EV/EBITDA (X) | 14.62 | 18.45 | 24.15 | 19.66 | 20.23 | |
| MarketCap/Net Operating Revenue (X) | 4.37 | 4.33 | 3.69 | 4.49 | 5.07 | |
| Retention Ratios (%) | 86.67 | 74.00 | 29.58 | 75.77 | 74.86 | |
| Price/BV (X) | 3.41 | 3.63 | 2.93 | 3.76 | 4.46 | |
| Price/Net Operating Revenue | 4.37 | 4.33 | 3.69 | 4.49 | 5.07 | |
| Earnings Yield | 0.06 | 0.03 | 0.02 | 0.03 | 0.03 |
15.12.2025
12.12.2025
25.11.2025
11.11.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz